Clinical significance of serum ProGRP expression in patients with SCLC
Abstract：Objective To investigate the expression of serum progastrin releasing peptide (ProGRP)and its clinical significance in patients with small cell lung cancer (SCLC). Methods Western blot enhanced chemiluminescence was used to detect serum ProGRP and NSE concentration of 37 cases of SCLC , 76 cases of NSCLC and 62 healthy controls. The correlation between the expression of ProGRP and clinicopathologic features of small cell lung cancer was analyzed. The methods to analyze the data were ANOVA and Fisher exact probability. Results Serum ProGRP levels of SCLC group was higher than that in control group (F=10.730,P<0.001); The sensitivity of ProGRP (67.6%)was the highest when compared with NSE (56.8%)and the detection sensitivity (70.3%)was significantly improved as ProGRP combined with NSE; Overexpression of ProGRP in small cell lung cancer was significantly correlated with NSE positive expression rate (P=0.012)and distant metastasis (P=0.027) but without any association with other clinicopathologic features. Conclusions ProGRP has a certain clinical significance in detection and the detection rate of SCLC can be improved when combined ProGRP with NSE. The expression of ProGRP in SCLC is significantly correlated with the positive rate of NSE , and it may be related to the development of SCLC.
Keywords：Progastrin releasing peptideNSESmall cell lung cancerDiagnosis
Publication Date：2016-01-01
Online Publishing Date：2025-08-15(First online date of this platform, not the publication date of the document)
Pages：4( 1784-1787 )